Hepatitis B Virus Infection Clinical Trial
Official title:
Maternal Screening and Antiviral Therapy in Pregnant Women to Reduce Mother-to-infant Transmission of Hepatitis B Virus
To investigate the efficacy of using antiviral therapy in third trimester of pregnancy to reduce mother-to-infant HBV transmission, and to access the safety of such treatment for mothers and infants.
This is a multi-centered study conducted in 12-16 collaborative hospitals in Taiwan, using tenofovir as antiviral therapy to reduce mother-to-infant transmission. The study group recruited pregnant women at 2nd to 3rd trimester receive tenofovir disoproxil fumurate (TDF) 2011-2018, June, and receive tenofovir alafenamide (TAF) 2018-2021. Control group did not receive antiviral treatment. Both group receive mother and infant follow-up up to 12 months after delivery. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05392387 -
Treatment and Prognosis of Patients With Chronic HBV Infection
|
||
| Recruiting |
NCT06023056 -
Hepatitis B Vaccination After Neonatal Surgery
|
||
| Recruiting |
NCT05051098 -
A Non-interventional Registry for Patients With Hepatitis B Virus Infection
|
||
| Recruiting |
NCT03864263 -
Hepatitis B Virus Infection in Immunized Children With HBsAg-positive Parents
|
||
| Completed |
NCT02798549 -
HBV Virions Bound Proteins
|
N/A | |
| Completed |
NCT00440297 -
Hepatitis B Vaccine Predialysis/Dialysis Study (V232-060)
|
Phase 3 | |
| Terminated |
NCT03762681 -
A Study of RO7239958 to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Volunteers and Participants With Chronic Hepatitis B Virus Infection
|
Phase 1 |